Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE:002399)
China
· Delayed Price · Currency is CNY 11.35
-0.09 (-0.79%)
At close: Mar 9, 2026
SHE:002399 Revenue
Shenzhen Hepalink Pharmaceutical Group had revenue of 1.38B CNY in the quarter ending September 30, 2025, with 11.82% growth. This brings the company's revenue in the last twelve months to 5.38B, down -0.96% year-over-year. In the year 2024, Shenzhen Hepalink Pharmaceutical Group had annual revenue of 5.26B, down -3.17%.
Revenue (ttm)
5.38B
Revenue Growth
-0.96%
P/S Ratio
2.82
Revenue / Employee
2.80M
Employees
1,926
Market Cap
15.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.26B | -172.06M | -3.17% |
| Dec 31, 2023 | 5.43B | -1.73B | -24.14% |
| Jan 1, 2023 | 7.16B | 794.23M | 12.48% |
| Jan 1, 2022 | 6.37B | 1.03B | 19.38% |
| Dec 31, 2020 | 5.33B | 707.42M | 15.30% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Guangdong Zhongsheng Pharmaceutical | 2.45B |
| Hybio Pharmaceutical | 898.10M |
| China Resources Jiangzhong Pharmaceutical Co.,Ltd | 4.24B |
| Nanjing King-Friend Biochemical Pharmaceutical | 3.76B |
| Shenzhen Kangtai Biological Products | 2.70B |
| Zhejiang Jiuzhou Pharmaceutical | 5.36B |
| Guobang Pharma | 5.94B |
| Shanghai Shyndec Pharmaceutical | 9.36B |